Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(15):1202-1203; doi:10.1093/jnci/92.15.1202
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vanchieri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanchieri, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 15, 1202-1203, August 2, 2000
© 2000 Oxford University Press

NEWS

Cutting Copper Curbs Angiogenesis, Studies Show

Cori Vanchieri

With the spotlight focused on angiostatin, endostatin, and a few other popular angiogenesis inhibitors, a handful of researchers are quietly targeting a trace element that appears to be crucial to tumor blood vessel growth—copper. Early patient studies are showing tumor response and low toxicity.

"We are learning that copper status is critical to the function of the angiogenic growth factors," wrote Steven Brem, M.D., in a 1999 article in Cancer Control. Vascular endothelial growth factor, basic fibroblast growth factor, tumor necrosis factor-{alpha}, and . . . [Full Text of this Article]

Early Promise

Drug Plus Diet

‘Difficult Tumors’


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Integr Cancer TherHome page
J. M. Wallace
Integrative Tumor Board: Glioblastoma Multiforme: Nutritional and Botanical Approach
Integr Cancer Ther, June 1, 2004; 3(2): 152 - 163.
[PDF]